Share of Clicks for top 10 US Pharma & Biotech Research and Development brands
Here are the Top 10 competitors in the industry by Share of Clicks for the last month.
| Domain | Share of clicks |
|---|---|
| abbvie.com | 12.6 |
| lilly.com | 10.92 |
| abbott.com | 9.97 |
| regeneron.com | 5.46 |
| gsk.com | 4.68 |
| pfizerforall.com | 4.02 |
| merck.com | 3.7 |
| jnj.com | 3.12 |
| evenity.com | 2.67 |
| sequencing.com | 2.55 |
| others | 40.31 |
- abbvie.com - 12.6%
- lilly.com - 10.92%
- abbott.com - 9.97%
- regeneron.com - 5.46%
- gsk.com - 4.68%
- pfizerforall.com - 4.02%
- merck.com - 3.7%
- jnj.com - 3.12%
- evenity.com - 2.67%
- sequencing.com - 2.55%
- others - 40.31%
Copyright © Adthena. All rights reserved.
In the PPC landscape, ‘others’ dominate with 40.31% click share, while ‘abbvie.com’ leads individual advertisers at 12.6%. ‘lilly.com’ follows with 10.92%, and ‘abbott.com’ at 9.97%.
Share of Spend for the top 10 US Pharma & Biotech Research and Development brands
Curious about your market position? Here you can see the Top 10 competitors in the industry by Share of Spend for the last month.
| Date | jnj.com | abbvie.com | pfizerforall.com | evenity.com | lilly.com | tecvayli.com | myriad.com | regeneron.com | capvaxive.com | goodrx.com |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025/12/01 | 0.16% | 4.15% | 7.72% | 0.76% | 13.16% | 4.72% | 2.39% | 3.73% | 4.98% | 2.72% |
| 2025/12/02 | 0.45% | 1.82% | 8.12% | 1.63% | 21.68% | 2.11% | 0.33% | 0.55% | 7.63% | 3.08% |
| 2025/12/03 | 0.21% | 1.64% | 7.37% | 0.54% | 18.06% | 2.57% | 1.55% | 0.19% | 3.17% | 1.92% |
| 2025/12/04 | 0.38% | 2.48% | 10.14% | 2.28% | 16.15% | 1.87% | 1.48% | 2.29% | 3.1% | 2.3% |
| 2025/12/05 | 0.37% | 1.9% | 7.94% | 1.03% | 12.56% | 2.51% | 2.69% | 2.46% | 2.39% | 1.06% |
| 2025/12/06 | 0.32% | 4.64% | 9.71% | 5.09% | 14.82% | 2.67% | 2.29% | 1.61% | 2.64% | 2.32% |
| 2025/12/07 | 0.33% | 4.49% | 7.3% | 5.01% | 11.88% | 3.05% | 2.02% | 1.68% | 0.6% | 2.35% |
| 2025/12/08 | 0.57% | 1.65% | 10.85% | 3.9% | 13.23% | 2.89% | 1.44% | 1.58% | 3.46% | 1.77% |
| 2025/12/09 | 0.41% | 1.07% | 8.17% | 2.47% | 12.66% | 2.51% | 2.23% | 2.14% | 2.98% | 1.79% |
| 2025/12/10 | 0.38% | 1.14% | 10.16% | 3.5% | 5.94% | 3.92% | 3.07% | 3.26% | 3.72% | 2.57% |
| 2025/12/11 | 0.24% | 1.77% | 8.4% | 5.68% | 14.96% | 2.36% | 2.33% | 2.08% | 2.89% | 2.39% |
| 2025/12/12 | 0.37% | 2.53% | 12.49% | 6.2% | 6.57% | 2.8% | 2.99% | 1.91% | 1.09% | 2.6% |
| 2025/12/13 | 0.54% | 6.62% | 10.76% | 4.4% | 6.87% | 2.28% | 3.41% | 1.18% | 3.33% | 1.53% |
| 2025/12/14 | 0.53% | 5.04% | 11.77% | 4.14% | 10.32% | 2.75% | 3.75% | 4.28% | 0.11% | 2.49% |
| 2025/12/15 | 0.44% | 3.95% | 10.34% | 3.79% | 16.34% | 3.06% | 3.25% | 0.61% | 0.1% | 2.33% |
| 2025/12/16 | 0.25% | 2.15% | 9.83% | 4.84% | 5.46% | 2.44% | 2.22% | 0.65% | 3.02% | 1.39% |
| 2025/12/17 | 6.34% | 0.63% | 6.64% | 4.52% | 9.79% | 2.25% | 2.03% | 1.3% | 4.37% | 2.62% |
| 2025/12/18 | 6.43% | 0.6% | 10.25% | 1.53% | 5.59% | 2.83% | 2.45% | 4.2% | 3.63% | 2.59% |
| 2025/12/19 | 5.36% | 0.77% | 5.99% | 5.73% | 11.23% | 2.18% | 2.74% | 3.11% | 2.99% | 1.52% |
| 2025/12/20 | 7% | 4.14% | 9.97% | 2.59% | 17.08% | 2.74% | 2.84% | 1.39% | 2.35% | 1.53% |
| 2025/12/21 | 0.35% | 5.2% | 9.98% | 5.33% | 12.05% | 2.41% | 2.82% | 3.6% | 2.53% | 2.15% |
| 2025/12/22 | 0.52% | 3.14% | 10.74% | 4.04% | 8.29% | 2.94% | 3.01% | 2.34% | 4.36% | 1.61% |
| 2025/12/23 | 0.46% | 2.7% | 10.04% | 3.25% | 5.63% | 2.72% | 3.6% | 2.02% | 2.18% | 0.45% |
| 2025/12/24 | 0.42% | 0.99% | 11.85% | 3.21% | 4.37% | 2.83% | 3.15% | 2.99% | 1.06% | 2.24% |
| 2025/12/25 | 0.33% | 3.98% | 5.58% | 6.49% | 5.28% | 2.61% | 3.65% | 0.59% | 2.61% | 2.11% |
| 2025/12/26 | 7.35% | 5.44% | 10.01% | 5.38% | 1.49% | 2.37% | 2.85% | 1.64% | 2.76% | 1.9% |
| 2025/12/27 | 7.94% | 3.98% | 11.01% | 5.96% | 5.89% | 2.39% | 2.15% | 0.57% | 3.03% | 2.5% |
| 2025/12/28 | 0.32% | 6.46% | 8.74% | 4.16% | 13.35% | 2.48% | 3.47% | 0.78% | 1.09% | 2.56% |
| 2025/12/29 | 0.29% | 5.68% | 10.26% | 6.07% | 7.38% | 2.96% | 2.3% | 4.25% | 1.03% | 1.77% |
| 2025/12/30 | 0.55% | 3.05% | 8.53% | 7.82% | 3.4% | 3.64% | 2.93% | 3.27% | 3.53% | 0% |
| 2025/12/31 | 9.7% | 4.75% | 3.97% | 3.71% | 3.31% | 3.23% | 2.62% | 0.98% | 0.08% | 0% |
- jnj.com
- abbvie.com
- pfizerforall.com
- evenity.com
- lilly.com
- tecvayli.com
- myriad.com
- regeneron.com
- capvaxive.com
- goodrx.com
Copyright © Adthena. All rights reserved.
In December 2025, Pfizerforall.com led with consistent high spend, peaking mid-month. Jnj.com saw spikes on the 17th, 26th, and 31st. Lilly.com fluctuated, starting strong, dipping mid-month, and ending lower.
Competitor Count for US Pharma & Biotech Research and Development
Ever wondered how many competitors you’re up against in your industry? Well look no further, here we can see the number of advertisers bidding over the last month.
| Date | Competitor Count |
|---|---|
| 2025/12/01 | 470 |
| 2025/12/02 | 454 |
| 2025/12/03 | 479 |
| 2025/12/04 | 487 |
| 2025/12/05 | 496 |
| 2025/12/06 | 498 |
| 2025/12/07 | 499 |
| 2025/12/08 | 495 |
| 2025/12/09 | 511 |
| 2025/12/10 | 523 |
| 2025/12/11 | 532 |
| 2025/12/12 | 518 |
| 2025/12/13 | 490 |
| 2025/12/14 | 509 |
| 2025/12/15 | 515 |
| 2025/12/16 | 515 |
| 2025/12/17 | 508 |
| 2025/12/18 | 508 |
| 2025/12/19 | 518 |
| 2025/12/20 | 500 |
| 2025/12/21 | 499 |
| 2025/12/22 | 518 |
| 2025/12/23 | 522 |
| 2025/12/24 | 513 |
| 2025/12/25 | 517 |
| 2025/12/26 | 500 |
| 2025/12/27 | 486 |
| 2025/12/28 | 486 |
| 2025/12/29 | 490 |
| 2025/12/30 | 498 |
| 2025/12/31 | 476 |
Copyright © Adthena. All rights reserved.
December saw a dynamic shift in distinct advertisers, starting at 470 and peaking at 532 mid-month. The month concluded with a slight dip to 476, reflecting a vibrant advertising landscape.
